Advertisement

Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021

Published:December 30, 2021DOI:https://doi.org/10.1016/j.amjmed.2021.11.019

      Abstract

      Chronic kidney disease affects approximately 10% of the population or 800 million people globally, with diabetes being the leading cause. The presence of chronic kidney disease with impaired kidney function or with albuminuria is associated with an increased risk of a progressive loss of renal function and increased risk of cardiovascular disease and excess mortality. Screening for chronic kidney disease is critically important because during the initial stages patients often have no symptoms and because we now have available recently approved multiple interventions that can reduce the high risks dramatically. Screening should be performed with regular measurement of albumin in the urine and creatinine or cystatin C in blood for estimation of kidney function. Regretfully recent data indicates that screening for albuminuria is conducted in only 20%-50% of people at risk depending on the setting. Clinicians need to perform regular screening and concomitant management of risk factors. Recent therapeutic options must be implemented to improve outcomes. Finally, a reduction in albuminuria after initiation of intervention constitutes a treatment target because it indicates improved prognosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2020; 395: 709-733
      2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Available at: https://diabetesatlas.org/. Accessed July 20, 2021.

        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Shlipak MG
        • Tummalapalli SL
        • Boulware LE
        • et al.
        The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
        Kidney Int. 2021; 99: 34-47
        • Iseki K
        • Iseki C
        • Ikemiya Y
        • Fukiyama K.
        Risk of developing end-stage renal disease in a cohort of mass screening.
        Kidney Int. 1996; 49: 800-805
        • Ruggenenti P
        • Perna A
        • Mosconi L
        • Pisoni R
        • Remuzzi G.
        Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
        Kidney Int. 1998; 53: 1209-1216
        • Ruggenenti P
        • Perna A
        • Gherardi G
        • et al.
        Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
        Lancet. 1999; 354: 359-364
        • Chen CH
        • Wu HY
        • Wang CL
        • et al.
        Proteinuria as a therapeutic target in advanced chronic kidney disease: a retrospective multicenter cohort study.
        Sci Rep. 2016; 6: 26539
        • Heerspink HJL
        • Greene T
        • Tighiouart H
        • et al.
        Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
        Lancet Diabetes Endocrinol. 2019; 7: 128-139
        • Afkarian M
        • Sachs MC
        • Kestenbaum B
        • et al.
        Kidney disease and increased mortality risk in type 2 diabetes.
        J Am Soc Nephrol. 2013; 24: 302-308
        • Groop PH
        • Thomas MC
        • Moran JL
        • et al.
        The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes.
        Diabetes. 2009; 58: 1651-1658
        • Wen CP
        • Chang CH
        • Tsai MK
        • et al.
        Diabetes with early kidney involvement may shorten life expectancy by 16 years.
        Kidney Int. 2017; 92: 388-396
        • Moyer VA
        Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2012; 157: 567-570
        • Qaseem A
        • Hopkins Jr., RH
        • Sweet DE
        • Starkey M
        • Shekelle P
        Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.
        Ann Intern Med. 2013; 159: 835-847
      3. Janssen. Prescribing Information. 2020.

        • Perkovic V
        • Jardine MJ
        • Neal B
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Heerspink HJL
        • Stefánsson BV
        • Correa-Rotter R
        • et al.
        Dapagliflozin in patients with chronic kidney disease.
        N Engl J Med. 2020; 383: 1436-1446
        • Bakris GL
        • Agarwal R
        • Anker SD
        • et al.
        Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.
        N Engl J Med. 2020; 383: 2219-2229
        • Pitt B
        • Filippatos G
        • Agarwal R
        • et al.
        Cardiovascular events with finerenone in kidney disease and type 2 diabetes.
        N Engl J Med. 2021; 385: 2252-2263
      4. US Food and Drug Administration. FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease#:∼:text=FDA%20has%20approved%20Kerendia%20(finerenone,associated%20with%20type%202%20diabetes. Accessed August 5, 2021.

        • de Boer IH
        • Caramori ML
        • Chan JCN
        • et al.
        KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
        Kidney Int. 2020; 98: S1-S115
        • Buse JB
        • Wexler DJ
        • Tsapas A
        • et al.
        2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetologia. 2020; 63: 221-228
        • American Diabetes Association
        11. Microvascular complications and foot care: standards of medical care in diabetes–2020.
        Diabetes Care. 2020; 43: S135-S151
        • Stempniewicz N
        • Vassalotti JA
        • Cuddeback JK
        • et al.
        Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations.
        Diabetes Care. 2021; 44: 2000-2009
        • Alfego D
        • Ennis J
        • Gillespie B
        • et al.
        Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database.
        Diabetes Care. 2021; 44: 2025-2032
        • Tuttle KR
        • Alicic RZ
        • Duru OK
        • et al.
        Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry.
        JAMA Netw Open. 2019; 2e1918169
        • Persson F
        • Charles M
        • Povlsen JV
        • Knudsen ST.
        Improving frequency of urinary albumin testing in type 2 diabetes in primary care - An analysis of cross-sectional studies in Denmark.
        Prim Care Diabetes. 2021; 16: 1007-1011
      5. Diabetes UK. Position statement: the future of the quality and outcomes framework in England. Available at: https://www.diabetes.org.uk/professionals/position-statements-reports/quality-outcomes-framework-england. Accessed July 5, 2021.

        • Feakins B
        • Oke J
        • McFadden E
        • et al.
        Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD.
        BMJ Open. 2019; 9e028062
      6. National Kidney Foundation. Public awareness initiative for AAKH announced as a public–private partnership with NKF and ASN. Available at: https://www.kidney.org/news/aakh-announced-public-private-partnership-nkf-asn. Accessed July 5, 2021.

      7. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States. Available at: https://nccd.cdc.gov/CKD/Default.aspx/. Accessed July 5, 2021.

        • Murphy DP
        • Drawz PE
        • Foley RN.
        Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States.
        J Am Soc Nephrol. 2019; 30: 1314-1321
        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
        Kidney Int. 2020; 98: S1-S115
        • Buse JB
        • Wexler DJ
        • Tsapas A
        • et al.
        2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2020; 43: 487-493
        • Mann JFE
        • Orsted DD
        • Buse JB.
        Liraglutide and renal outcomes in type 2 diabetes.
        N Engl J Med. 2017; 377: 2197-2198
        • Gerstein HC
        • Colhoun HM
        • Dagenais GR
        • et al.
        Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
        Lancet. 2019; 394: 131-138